Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival.

Autor: Masubuchi, Ken1 (AUTHOR), Imai, Hisao1,2 (AUTHOR) m06701014@gunma-u.ac.jp, Wasamoto, Satoshi3 (AUTHOR), Tsuda, Takeshi4 (AUTHOR), Minemura, Hiroyuki5 (AUTHOR), Nagai, Yoshiaki6 (AUTHOR), Yamada, Yutaka7 (AUTHOR), Kishikawa, Takayuki8 (AUTHOR), Umeda, Yukihiro9 (AUTHOR), Shiono, Ayako2 (AUTHOR), Takechi, Hiroki3 (AUTHOR), Shiihara, Jun6 (AUTHOR), Kaira, Kyoichi2 (AUTHOR), Kanazawa, Kenya5 (AUTHOR), Taniguchi, Hirokazu4 (AUTHOR), Kaburagi, Takayuki7 (AUTHOR), Kagamu, Hiroshi2 (AUTHOR), Minato, Koichi1 (AUTHOR)
Zdroj: Thoracic Cancer. Oct2022, Vol. 13 Issue 19, p2776-2785. 10p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje